ON-TARGET: A Logic-Gated, Multi-Input
Nanoplatform for Spatiotemporally Controlled
Precision Therapeutics

Defensive Publication

December 15, 2025

Abstract
We introduce ON-TARGET, a modular, logic-gated nanoplatform for highly specific and temporally precise
delivery of diverse therapeutic cargoes. The core of ON-TARGET is a stabilized DNA origami box (DOB)
that encapsulates a payload such as small-molecule drugs, biologics, or nucleic-acid-based agents (e.g., siRNA,
mRNA, or CRISPR ribonucleoproteins). The system functions as a physical Biological AND Gate, requiring
the simultaneous satisfaction of two orthogonal inputs for payload release: a cell- or tissue-specific Input A
(Biomarker Latch) and a clinician-controlled Input B (Localized Magnetothermal Actuation). In advanced
modes, an optional Input C (Photo-Cleavable Fail-Safe) can be added. This multi-input logic, expressed as
Release = A ∧ B or Release = A ∧ B ∧ C,
provides stringent spatial and temporal control, enabling safer and more effective interventions across regen￾erative medicine, cancer therapy, autoimmune disease management, and gene therapy.

1 Strategic Positioning and Clinical Need

1.1 Limitations of Conventional Nanomedicine
Most existing nanomedicine platforms (liposomes, polymeric nanoparticles, viral vectors) suffer from:
• Poor Spatial Specificity: Passive accumulation in non-target organs (e.g., liver, spleen) leads to off￾target toxicity.
• Lack of Temporal Control: Payloads are typically released immediately upon uptake or environmental
stimulus, decoupled from optimal clinical timing.

1.2 Platform-Level Innovation
ON-TARGET addresses these limitations by embedding explicit, verifiable multi-input Boolean logic at the
single-nanodevice level. Input A enforces localization to a pathological site, Input B enforces clinician￾directed timing, and optional Input C enforces a third independent physical constraint. This design trans￾forms the nanocarrier from a passive vehicle into a programmable therapeutic gatekeeper applicable to any
indication where conditional release is beneficial.

2 Nanodevice Design and Mechanisms
The ON-TARGET nanodevice is a DNA origami box encapsulating the therapeutic cargo. Scaffold and
staple strands can include chemical modifications (e.g., phosphorothioate linkages) and surface PEGylation
to increase nuclease resistance, reduce immune recognition, and prolong circulation time.
1

2.1 Input A: Biological Latch (Spatial Control)

Input A implements a mandatory specificity check to ensure that the device engages only with intended cell
populations.
• Mechanism: Two distinct DNA aptamers, Aptamer1 and Aptamer2
, are placed in a hinge or locking
region of the DOB. Each aptamer recognizes either distinct epitopes on a single target protein or two
co-localized markers on the same cell type.
• Logic: The latch is designed as an AND condition,
A = Bind(Aptamer1
) ∧ Bind(Aptamer2),
such that both binding events must occur to induce a conformational change that unlocks the first latch.
This dual-epitope or dual-marker requirement increases specificity and reduces false-positive activation.

2.2 Input B: Localized Nanoscale Magnetothermal Actuation (Temporal Con￾trol)
Input B provides an externally controllable, non-invasive temporal trigger.
• Mechanism: The second latch is a DNA duplex tethered within nanometers of a superparamagnetic
iron oxide nanoparticle (SPION). The sequence and length of this duplex are chosen such that its melting
temperature Tm lies approximately 10◦C to 15◦C above physiological temperature, e.g.,
Tm ≈ 47◦C − 52◦C.
• Thermodynamic Design: The duplex is designed and validated using nearest-neighbor DNA thermo￾dynamic models under physiological ionic strength. Minor groove binders or other stabilizing agents may
be used to suppress thermal jitter and ensure that spontaneous melting at 37◦C is negligible.
• Actuation: When an alternating magnetic field (AMF) is applied, the SPION generates localized heat.
The temperature in the immediate nanoscale vicinity of the SPION exceeds Tm while bulk tissue remains
near physiological temperature, causing selective melting of the latch duplex and satisfying the temporal
condition B = 1.

2.3 Optional Input C: Photo-Cleavable Fail-Safe
For indications requiring maximal safety (e.g., CNS or systemic gene therapy), an optional third input is
added as a final release gate.
• Mechanism: A photo-cleavable linker (PCL) is inserted into the final opening pathway of the DOB. Even
if Inputs A and B are satisfied, the box remains locked until the PCL is cleaved.
• Deep-Tissue Control: Upconversion nanoparticles (UCNPs) can be co-integrated so that tissue-penetrant
near-infrared (NIR) light is absorbed and converted into higher-energy photons capable of cleaving the
PCL. This defines Input C, completing a three-input AND logic:
Release = A ∧ B ∧ C.

3 Versatile Therapeutic Applications

Because ON-TARGET decouples the control logic (latches and triggers) from the nature of the payload, it
can be rapidly adapted across multiple clinical domains.

3.1 Regenerative Medicine and Tissue Repair
• Growth Factor Delivery: DOBs can encapsulate NGF, FGF, VEGF, or other trophic factors, releasing
them only in damaged tissues expressing specific regeneration-associated markers.
• Stem and Progenitor Cell Modulation: Devices can target progenitor cells to deliver differentiation
cues or survival factors in demyelinating disease, spinal cord injury, or myocardial infarction.

3.2 Cancer Therapy and Immuno-Oncology
• Cytotoxic Payloads: Doxorubicin or TRAIL agonists are confined inside the DOB until both tumor￾specific markers (Input A) and AMF (Input B) are present, reducing systemic toxicity.
• Immune Modulation: The platform can deliver checkpoint inhibitors, cytokines, or DNA-origami-based
T-cell engagers to reshape the tumor immune microenvironment.

3.3 Autoimmune and Inflammatory Diseases
• Tolerogenic Therapy: ON-TARGET can deliver agents that induce regulatory T cells or tolerogenic
antigen-presenting cells, limiting autoreactive responses.
• Localized Anti-Inflammatory Delivery: Anti-inflammatory small molecules or cytokines can be se￾lectively released at sites of high NF-κB activity in joints, CNS lesions, or other inflamed tissues.

3.4 Gene Therapy and Gene Silencing
• CRISPR-Based Editing: Cas9-gRNA or base editor complexes are encapsulated inside the DOB and
only released where disease-defining markers are present and the clinician applies the external trigger.
• RNA Interference: siRNA or miRNA can be delivered to silence pathogenic genes in a cell-type-specific
and time-locked manner.

4 Integrated System Logic and Operation

4.1 Standard Mode (Dual-Input AND)
In standard configuration, the payload is released only when both spatial and temporal constraints are
satisfied:
Release = A ∧ B.

4.2 Maximum Safety Mode (Triple-Input AND)
For high-risk interventions, the system can be configured with the additional photo-cleavable linker:
Release = A ∧ B ∧ C.

5 Translational Outlook and Safety Considerations
ON-TARGET is conceived as a platform technology rather than a single product. Key translational con￾siderations include manufacturability, regulatory alignment, and ethical governance, all supported by its